Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Highland Capital Management Reveals Investment In Relypsa (RLYP)

Page 1 of 21

Relypsa Inc (NASDAQ:RLYP) has proved to be a great short-term investment and  James Dondero is one of those who profited, as his fund, Highland Capital Management has recently initiated a new position. According to a filing with the Securities and Exchange Commission, Dondero and Highland Capital have amassed 5.91 million shares, which amount to approximately 13.2% of the company’s common stock.

A biopharmaceutical company developing gastrointestinal medicines, Relypsa Inc (NASDAQ:RLYP) is set to be acquired by the Swiss-based Galenica Group for $32 per share, which valued as the company at $1.53 billion. Relypsa will be merged with Galenica’s Vifor Pharma division and later be spun off into a public company that will be one of the largest pharmaceutical company focused on nephrology, cardiology and gastroenterology medicine. One of the main attractions for Galenica was Relypsa’s Veltassa, an FDA-approved treatment for hyperkalemia. With AstraZeneca plc (ADR) (NYSE:AZN)’s candidate out of the game, Veltassa could become the leader in a $6 billion market.

medications-pharmacy drugs

At the end of the first quarter, some 33.4% of Relypsa Inc (NASDAQ:RLYP)’s common stock was held by 14 investors tracked by Insider Monkey, down from 21 a quarter before. Among the most prominent investors holding this stock was Samuel Isaly‘s OrbiMed Advisors. According to its latest 13F filing, the fund held exactly 7.4 million shares, unchanged over the quarter. James H. Litinsky’s JHL Capital Group reportedly held 3 million shares of Relypsa, up by 34% from the previous quarter.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Highland Small-Cap Equity Fund 37,000 0 37,000 0 37,000 0.1%
Highland Capital Management Fund Advisors 0 37,000 0 37,000 37,000 0.1%
Strand Advisors XVI, Inc 0 37,000 0 37,000 37,000 0.1%
NexPoint Credit Strategies Fund 2,600,000 0 2,600,000 0 2,600,000 5.8%
NexPoint Advisors 0 2,600,000 0 2,600,000 2,600,000 5.8%
NexPoint Advisors GP 0 2,600,000 0 2,600,000 2,600,000 5.8%
Highland Select Equity Master Fund 3,277,900 0 3,277,900 0 3,277,900 7.3%
Highland Select Equity Fund GP 0 3,277,900 0 3,277,900 3,277,900 7.3%
Highland Select Equity GP 0 3,277,900 0 3,277,900 3,277,900 7.3%
Highland Capital Management 0 3,277,900 0 3,277,900 3,277,900 7.3%
Strand Advisors, Inc 0 3,277,900 0 3,277,900 3,277,900 7.3%
James D. Dondero 0 5,914,900 0 5,914,900 5,914,900 13.2%

Page 1 of 21 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

Relypsa, Inc.

(Name of Issuer)

Common stock, par value $0.001 per share

(Title of Class of Securities)

75931106

(CUSIP Number)

July 27, 2016

(Date of Event Which Requires Filing of this Statement)

 

 

Check the
appropriate box to designate the rule pursuant to which this Schedule is filed:

x Rule
13d-1(b)

¨ Rule 13d-1(c)

¨ Rule 13d-1(d)

Follow Relypsa Inc (NASDAQ:RLYP)
Trade (NASDAQ:RLYP) Now!
Page 1 of 21

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!